With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Understanding what’s out there for recurrent / refractory Ewing sarcoma can feel like a grab-all so fortunately the first phase 3 trial for this population has established high-dose ifosfamide as the most effective regimen. | McCabe, ASCO 2022
Comments
Post a Comment